Corbus Pharmaceuticals I...

AI Score

0

Unlock

11.15
-0.18 (-1.59%)
At close: Feb 06, 2025, 2:03 PM
undefined%
Bid 11.09
Market Cap 135.80M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -4.71
PE Ratio (ttm) -2.37
Forward PE n/a
Analyst Buy
Ask 11.17
Volume 189,283
Avg. Volume (20D) 272,435
Open 11.57
Previous Close 11.33
Day's Range 10.77 - 11.58
52-Week Range 9.11 - 61.90
Beta undefined

About CRBP

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the act...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 27, 2014
Employees 19
Stock Exchange NASDAQ
Ticker Symbol CRBP

Analyst Forecast

According to 8 analyst ratings, the average rating for CRBP stock is "Buy." The 12-month stock price forecast is $62.5, which is an increase of 460.54% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
4 months ago
-62.26%
Corbus Pharmaceuticals Holdings shares are trading... Unlock content with Pro Subscription
7 months ago
+14.68%
Corbus Pharmaceuticals Holdings shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $77 to $82.